To investigate the prevalence of sarcopenia and its impact on clinical outcomes in patients with esophageal, gastric, or colorectal cancer (EC, GC, and CRC) receiving neoadjuvant therapy through Meta-analysis. We searched the PubMed, Embase databases, and Cochrane Library for the prevalence of sarcopenia and its impact on clinical outcomes in EC, GC, or CRC patients treated with neoadjuvant therapy (NAT) from inception to November 2022. The primary endpoints were the prevalence of sarcopenia and overall survival in patients with EC, GC, or CRC treated with NAT. Secondary outcomes included recurrence-free survival, total postoperative complications, grade 3–4 chemotherapy toxicity, and 30-day mortality after surgery. Thirty-one retrospective studies with 3651 subjects were included. In a fixed-effects model, the prevalence of muscle loss was higher in patients with EC, GC, or CRC at 50% (95% CI = 42% to 58%). The results of the multivariate analysis showed that preoperative patients with sarcopenia had a 1.91 times shorter overall survival (95% CI = 1.61–2.27) and a 1.77 times shorter recurrence-free survival time (95% CI = 1.33–2.35) than patients without sarcopenia, and that patients with sarcopenia had a higher risk of total postoperative complications than patients without sarcopenia OR = 1.27 (95% CI = 1.03–1.57). However, the two groups had no statistical difference in grade 3–4 chemotherapy toxicity (P = 0.84) or 30-d postoperative mortality (P = 0.88). The prevalence of sarcopenia in patients with EC, GC, or CRC during NAT is high, and it is associated with poorer clinical outcomes. Clinicians should closely monitor the changes in patients’ body composition and guide patients to carry out a reasonable diet and appropriate exercise to improve their poor prognosis and quality of life. CRD42023387817.
Background: Breast cancer patients often experience significant psychological challenges, particularly fear of cancer recurrence (FCR), which is a prevalent and distressing concern following diagnosis. FCR can lead to heightened emotional distress, including anxiety and depression. Resilience, the ability to adapt positively to adversity, may play a crucial role in mitigating these negative emotional outcomes. This study aims to explore the heterogeneity of FCR among breast cancer patients and examine the moderating effect of resilience on the relationship between FCR and emotional distress.Materials and methods: A cohort of 398 breast cancer patients participated in the Be Resilient to Breast Cancer (BRBC) program between May and December 2023. Surveys were administered to assess FCR, resilience, and emotional distress levels. Data were analyzed using two approaches: latent profile analysis (LPA) to identify distinct FCR profiles and moderation analysis to evaluate the role of resilience.Results: Three distinct FCR profiles were identified: low (27.5%), middle (53%), and high (19.5%). Resilience significantly moderated the association between FCR and anxiety (B = 0.115, SE = 0.046, P = 0.014), but no significant moderating effect was observed for depression.Discussion: The findings highlight significant heterogeneity in FCR among breast cancer patients, with a substantial proportion experiencing moderate to high levels of FCR. Resilience was found to buffer the impact of FCR on anxiety, suggesting that interventions aimed at enhancing resilience could alleviate anxiety related to FCR in this population. These results underscore the importance of incorporating resilience-focused strategies into psychological therapies for breast cancer patients.
11 October 2025 in Asia-Pacific Journal of Oncology Nursing
Demoralization and loss of dignity frequently co-occur among individuals with cancer. However, their symptom-level associations remain poorly characterized. This study aimed to delineate the underlying pathways linking demoralization and dignity loss in breast cancer survivors and to identify potential symptom targets for intervention. A total of 411 female breast cancer survivors were assessed using the Demoralization Scale II and the Patient Dignity Inventory. A Gaussian graphical model was used to identify central and bridge symptoms, while a Bayesian network model estimated the directional associations and potential causal pathways between demoralization and dignity-related symptoms. Computer-simulated intervention analyses were conducted to determine which symptom reduction would yield the greatest decrease in overall network activation. In the Gaussian network, illness uncertainty emerged as the most central symptom (strength = 1.20), and loss of life meaning as the principal bridge symptom (bridge strength = 0.30). The Bayesian network identified distress as an upstream node triggering downstream cascades from demoralization to dignity loss. Simulation analyses indicated that reducing distress led to the largest decrease in global network activation (from 5.3% to 1.9%). This study elucidates the symptom-level mechanisms through which demoralization contributes to dignity loss in breast cancer survivors, highlighting loss of life meaning as a key bridging factor. Targeting distress may represent an effective intervention strategy to concurrently alleviate demoralization and preserve dignity.